Oragenics Files 8-K on Agreement and Listing Concerns
Ticker: OGEN · Form: 8-K · Filed: Oct 21, 2025 · CIK: 1174940
Sentiment: mixed
Topics: material-agreement, listing-rule, delisting-risk
TL;DR
Oragenics 8-K: Material agreement signed, but listing rule concerns arise.
AI Summary
Oragenics, Inc. filed an 8-K on October 21, 2025, reporting a material definitive agreement and a notice of delisting or failure to meet listing standards. The filing date for the earliest event reported is October 16, 2025. The company is incorporated in Florida and its principal executive offices are located in Sarasota, FL.
Why It Matters
This filing indicates potential significant changes or challenges for Oragenics, Inc. regarding its listing status and material agreements, which could impact its stock and operations.
Risk Assessment
Risk Level: high — The mention of 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' suggests significant financial or operational distress that could lead to the company's stock being delisted.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- October 16, 2025 (date) — Earliest event reported
- October 21, 2025 (date) — Date of Report
- Florida (location) — State of incorporation
- Sarasota, FL (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Oragenics, Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What specific listing rule or standard has Oragenics, Inc. failed to satisfy?
The filing does not provide specific details on which listing rule or standard was not met.
What is the earliest date of the events reported in this 8-K filing?
The earliest event reported is dated October 16, 2025.
Where are Oragenics, Inc.'s principal executive offices located?
Oragenics, Inc.'s principal executive offices are located at 1990 Main Street, Suite 750, Sarasota, FL 34236.
What is the SIC code for Oragenics, Inc.?
The Standard Industrial Classification (SIC) code for Oragenics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,227 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2025-10-21 07:45:43
Key Financial Figures
- $2,500,000 — reported, Ladenburg claimed it was due $2,500,000 in connection with the Company's purcha
- $700,000 — Settlement Agreement, the Company paid $700,000 to Ladenburg in exchange for a mutual r
- $2,000,000 — es stockholders' equity of no less than $2,000,000 if the Company has sustained losses fro
- $4 million — company to have stockholders' equity of $4 million or more if the listed company has repor
- $6 million — company to have stockholders' equity of $6 million or more if the listed company has repor
- $16.5 million — roceeds to the Company of approximately $16.5 million before deducting placement agent fees a
- $2.75 million — its ATM program, for gross proceeds of $2.75 million before subtracting commission and legal
- $4.45 million — roceeds to the Company of approximately $4.45 million before deducting placement agent fees a
- $6.0 m — Company's stockholder's equity exceeds $6.0 million, as of October 18, 2025. On Oct
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-25-018725.txt ( ) — 223KB
- ogen-20251016.xsd (EX-101.SCH) — 3KB
- ogen-20251016_lab.xml (EX-101.LAB) — 33KB
- ogen-20251016_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 21 st day of October 2025. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Executive Officer